Medicxi Announces $400m Medicxi IV

  • Fund to focus on its pioneering ‘asset-centric’ investment model, backing visionary biopharma entrepreneurs and drug hunters along the full drug development spectrum

 27 July 2023, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces its $400 million Medicxi IV fund. The new fund will continue to support drug hunters with clear product visions to deliver transformative therapies for patients.

Read more…